MK-3641

· ALK-Abelló A/S

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-3641, covering 2016-01-18 to 2016-01-18. Get the full timeline:

Most recent: Clinical Trial Update: Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006) [Phase 4]

See pricing